Cardiovascular Events
0
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Monoclonal Antibody
1100%
+ 1 programs with unclassified modality
Competitive Landscape
2 companies ranked by most advanced pipeline stage
AstraZenecaCAMBRIDGE, United Kingdom
1 programSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular EventN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
2028
2029
IQVIATezepelumab
AstraZenecaSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Clinical Trials (2)
Total enrollment: 16,728 patients across 2 trials
Tezspire Cardiac Events PASS
Start: Sep 2025Est. completion: May 202916,640 patients
N/ARecruiting
NCT01395550AstraZenecaSecondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Secondary Prevention Treatment in Patients Who Have Suffered a Cardiovascular Event
Start: Jan 2010Est. completion: Jul 201088 patients
N/ACompleted
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 16,728 patients
2 companies competing in this space